

Apraglutide

Cat. No.:	HY-P1714	
CAS No.:	1295353-98-8	
Molecular Formula:	C ₁₇₂ H ₂₆₃ N ₄₃ O ₅₂	
Molecular Weight:	3765.25	HGDGFSDEX FTILDLLAAR DFINWLIQTK ITD-NH ₂
Sequence:	HGDGFSDEX FTILDLLAAR DFINWLIQTK ITD-NH ₂	
Sequence Shortening:	His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Nle-D-Phe-Thr-Ile-Leu-Asp-Leu-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-NH ₂	
Target:	Others	
Pathway:	Others	
Storage:	Please store the product under the recommended conditions in the COA.	

BIOLOGICAL ACTIVITY

Description	Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum ^[1] .								
In Vivo	Apraglutide (FE 203799; 5 mg/kg/dose, subcutaneously, twice on days 0 and 4 postsurgery) treated piglets are healthy, have significant lower fecal fat and energy losses and exhibit intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth on day 7 ^[1] . <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>Animal Model:</td> <td>NewbornDuroc piglets, 2–5 days old and weighing between 2-2.6 kg^[1].</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg/dose.</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneously, twice on days 0 and 4 postsurgery.</td> </tr> <tr> <td>Result:</td> <td>On day 7, treated piglets were healthy, had significant lower fecal fat and energy losses and exhibited intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth.</td> </tr> </table>	Animal Model:	NewbornDuroc piglets, 2–5 days old and weighing between 2-2.6 kg ^[1] .	Dosage:	5 mg/kg/dose.	Administration:	Subcutaneously, twice on days 0 and 4 postsurgery.	Result:	On day 7, treated piglets were healthy, had significant lower fecal fat and energy losses and exhibited intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth.
Animal Model:	NewbornDuroc piglets, 2–5 days old and weighing between 2-2.6 kg ^[1] .								
Dosage:	5 mg/kg/dose.								
Administration:	Subcutaneously, twice on days 0 and 4 postsurgery.								
Result:	On day 7, treated piglets were healthy, had significant lower fecal fat and energy losses and exhibited intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth.								

REFERENCES

[1]. Slim GM, et al. Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum. JPEN J Parenter Enteral Nutr. 2019 Jan 6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA